Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Windtree TherapeuticsWINT Cash-to-Debt is 0.02 as of Sep. 2025, which is 99% below its 10-year median of 1.68. The stock has 2 warning signs investors should review. Among 1,397 Biotechnology companies, Windtree Therapeutics ranks worse than 98.35% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Windtree Therapeutics's cash to debt ratio for the quarter that ended in Sep. 2025 was 0.02.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Windtree Therapeuticscouldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2025.
The historical rank and industry rank for Windtree Therapeutics's Cash-to-Debt or its related term are showing as below:
WINT'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 1.68 Max: No Debt
Current: 0.02
During the past 13 years, Windtree Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.02. And the median was 1.68.
WINT's Cash-to-Debt is ranked worse than 98.35% of 1397
companies
in the Biotechnology industry
Industry Median: 6.72
vs WINT: 0.02
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Windtree Therapeutics Cash-to-Debt Related Terms
Windtree Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Windtree Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
WINT vs LIPO, ITRMF, IOBTQ: Cash-to-Debt Comparison
For the Biotechnology subindustry, Windtree Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windtree Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Windtree Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windtree Therapeutics (WINT) has a Cash-to-Debt of 0.02 as of Sep. 2025. This is 99% below median its historical median of 1.68. Over the past decade, Windtree Therapeutics' Cash-to-Debt has ranged from 0.02 to 10,000.00. According to the industry distribution chart, Windtree Therapeutics ranks #1374 out of 1397 companies in the Biotechnology industry, placing it in the top 98.4%.
Is Windtree Therapeutics' Cash-to-Debt too high?
Windtree Therapeutics' current Cash-to-Debt of 0.02 is 99% below median its 10-year median of 1.68. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.72. Windtree Therapeutics' value of 0.02 is 99.7% below this industry median. Based on the distribution chart, Windtree Therapeutics ranks #1374 out of 1397 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Windtree Therapeutics' Cash-to-Debt compare to LIPO and ITRMF?
According to the Biotechnology industry distribution chart, Windtree Therapeutics ranks #1374 out of 1397 companies for Cash-to-Debt. This places Windtree Therapeutics in the lower half of its industry. The industry median Cash-to-Debt is 6.72. Windtree Therapeutics' value of 0.02 is 99.7% below this benchmark. Historically, Windtree Therapeutics' own Cash-to-Debt has ranged from 0.02 to 10,000.00 over the past decade. While the company's 10-year median is 1.68 vs. the industry median of 6.72, Windtree Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.72, based on 1,397 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windtree Therapeutics's current Cash-to-Debt of 0.02 is 99.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windtree Therapeutics's current Cash-to-Debt is 0.02, which is 99% below median its own 10-year median of 1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windtree Therapeutics stock overvalued right now?
Windtree Therapeutics (WINT) has a current Cash-to-Debt of 0.02. The current Cash-to-Debt is 0.02, which is 99% below median its 10-year median of 1.68 and 99.7% below the Biotechnology industry median of 6.72. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Windtree Therapeutics (WINT), the current Cash-to-Debt is 0.02 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WINT has been successfully added to your 
